TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Inhibikase Therapeutics
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering  of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics is conducting a public offering of common stock and pre-funded warrants, raising approximately $100 million to support its clinical-stage pharmaceutical development for pulmonary arterial hypertension.

Insights
IKT   neutral

The company is raising capital through a standard public offering, which indicates ongoing business development without strong positive or negative implications